Sugi Predict

Sugi Predict / Targets / BCL6B

BCL6B

B-cell CLL/lymphoma 6 member B protein · Q8N143 · BCL6B on Sugi Atlas →

1,735 patent compounds predicted against BCL6B, 1,377 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL20284237 SCHEMBL20284237 1.00 1/20
SCHEMBL22932325 SCHEMBL22932325 0.86 1/20
SCHEMBL20284550 SCHEMBL20284550 0.85 1/20
SCHEMBL20284171 SCHEMBL20284171 0.83 1/20
SCHEMBL20284495 SCHEMBL20284495 0.78 1/20
SCHEMBL21774733 SCHEMBL21774733 0.77 1/20
SCHEMBL20284494 SCHEMBL20284494 0.75 1/20
SCHEMBL20284173 SCHEMBL20284173 0.75 1/20
SCHEMBL20284544 SCHEMBL20284544 0.74 1/20
SCHEMBL20284548 SCHEMBL20284548 0.74 1/20
SCHEMBL21787648 SCHEMBL21787648 0.74 1/20
SCHEMBL22932327 SCHEMBL22932327 0.74 1/20
SCHEMBL20284174 SCHEMBL20284174 0.73 1/20
SCHEMBL22932326 SCHEMBL22932326 0.73 1/20
SCHEMBL20284076 SCHEMBL20284076 0.70 1/20
SCHEMBL20284079 SCHEMBL20284079 0.69 1/20
SCHEMBL20284491 SCHEMBL20284491 0.69 1/20
SCHEMBL22932324 SCHEMBL22932324 0.69 1/20
SCHEMBL20284564 SCHEMBL20284564 0.69 1/20
SCHEMBL20284408 SCHEMBL20284408 0.68 1/20

Clinical trials — most relevant to BCL6B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients PHASE3UNKNOWN
Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma PHASE3UNKNOWN
Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma PHASE2ACTIVE_NOT_RECRUITING
Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma PHASE2RECRUITING
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma PHASE1/PHASE2RECRUITING
A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations PHASE2ACTIVE_NOT_RECRUITING
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma PHASE1/PHASE2RECRUITING
MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma PHASE1/PHASE2WITHDRAWN
Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis PHASE2COMPLETED
DALY II Japan/MB-CART2019.1 for DLBCL PHASE2RECRUITING
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma PHASE1/PHASE2RECRUITING
SPC2996 in Chronic Lymphocytic Leukaemia PHASE1/PHASE2COMPLETED
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas PHASE1/PHASE2COMPLETED
Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI PHASE2UNKNOWN
Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma PHASE1/PHASE2WITHDRAWN
Study of Acalabrutinib and Tafasitamab in MZL Patients PHASE2ACTIVE_NOT_RECRUITING
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) PHASE2COMPLETED
A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies PHASE2COMPLETED
Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA PHASE1RECRUITING
Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma PHASE1UNKNOWN
A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma PHASE1COMPLETED
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies PHASE1RECRUITING
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL PHASE1COMPLETED
CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies EARLY_PHASE1UNKNOWN
Anti CD19 Gene Therapy for B-cell Lymphoma nanRECRUITING
Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL) nanRECRUITING
Proof of Concept for Real-time Multicentric Monitoring of MRD by PET and ctDNA in Aggressive B-Cell Lymphomas nanNOT_YET_RECRUITING
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL nanCOMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN
Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a BCL6B binder may also engage these)

ProteinNameSimilarity
O88282 — 1.000 O88282 →
Q811H0 — 0.992 Q811H0 →
B2RXF5 — 0.987 B2RXF5 →
B1WBS3 — 0.987 B1WBS3 →
Q9UFB7 — 0.987 Q9UFB7 →
Q90850 — 0.986 Q90850 →
Q8WUU4 — 0.983 Q8WUU4 →
Q6PD29 — 0.982 Q6PD29 →
Q8JZL0 — 0.982 Q8JZL0 →
Q96JB3 — 0.982 Q96JB3 →
Q9BU19 — 0.981 Q9BU19 →
Q9P0T4 — 0.981 Q9P0T4 →
Q8NCA9 — 0.981 Q8NCA9 →
O15015 — 0.981 O15015 →
Q96SZ4 — 0.981 Q96SZ4 →
Q504L7 — 0.980 Q504L7 →
TESK1 Dual specificity testis-specific protein kinase 1 0.980 landscape →
Q9JLZ6 — 0.980 Q9JLZ6 →
Q63572 — 0.980 Q63572 →
Q80XI6 — 0.980 Q80XI6 →
Q5R4P8 — 0.979 Q5R4P8 →
Q8CDC7 — 0.979 Q8CDC7 →
Q91X45 — 0.979 Q91X45 →
Q6ZN55 — 0.979 Q6ZN55 →
Q8BXX2 — 0.979 Q8BXX2 →
Q8VDG6 — 0.979 Q8VDG6 →
P10074 — 0.979 P10074 →
Q5RJR4 — 0.979 Q5RJR4 →
A0JNJ4 — 0.978 A0JNJ4 →
Q9UQQ2 — 0.978 Q9UQQ2 →